Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
structural biology in at least one technique is also required. The Post: This post is part of the DRI-IMB network, an initiative of UKs Digital Research Infrastructure with the vision to integrate computing
-
network. This post is responsible for supporting the annual agent commission process, coordinating day-to-day operations for the Agent Team, maintaining accurate records, and ensuring timely and effective
-
projects, understand their target markets, and develop compelling and competitive propositions for them. To deliver plans, you’ll engage with a network of specialist experts in commercial, digital and
-
. About you You’ll bring experience of planning and implementing marketing operations and the ability to do so in a large and complex organisation. Your skills in developing plans based on data and insight
-
The University of Southampton is committed to excellence in all we do, applying our insights and inventiveness to solve complex engineering and environmental challenges. As a world-leading, research
-
significant capital investment to achieve Net Zero. This role will suit exceptional candidates with a track record of managing a complex portfolio for a Russell Group University. You will be adept
-
Scalable Quantum Devices for the Future Quantum Internet. We seek an outstanding experimental physicist to join the Hybrid Quantum Networks Lab (HQNL ) as part of the UK’s Integrated Quantum
-
of Southampton is committed to excellence in all we do, applying our insights and inventiveness to solve the most complex societal and environmental challenges. As a world-leading, research-intensive university
-
. Although this approach has led to the development of alloys such as Type 316, Alloy 617, 800H, and 709, the process remains slow, expensive, and inefficient. Creep-fatigue represents a complex interplay of
-
the Southampton Experimental Cancer Medicine Centre (ECMC) and the UK Clinical Research Facility (CRF) network, translational rich phase IIs linking with cancer discovery colleagues across the UK, to phase IIIs